Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Regulatory

New pharmaceutical legislation in Europe agreed

The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
Manufacturing

Why aseptic processing is critical for microsphere drug manufacturing

As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements
Research & Development

Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs

A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Subscribe now